COIOSDeep risk insights through multi-disciplinary research across the globe
A dirt road in the middle of a forest
Item refines Preprint · not peer-reviewed Added

New heart failure was slightly less common on tirzepatide than semaglutide

Among 424,269 matched pairs of patients with obesity in the TriNetX records, one-year new-onset heart failure was 1.0% on tirzepatide and 1.3% on semaglutide.

A retrospective study matched 424,269 patients with obesity starting tirzepatide to the same number starting semaglutide in the TriNetX records. One-year new-onset heart failure was 1.0% on tirzepatide against 1.3% on semaglutide. All-cause mortality was also lower on tirzepatide (HR 0.8), with atrial fibrillation or flutter at similar rates in both groups.

Why it is interesting: A head-to-head comparison of the two incretin drugs on a hard cardiac endpoint.

Source
medRxiv, 26 September 2026
Paper
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide
Authors
Al-Nusair M, Haddad TA, Khurana S, Al-Nusair J
DOI
10.64898/2026.09.21.26363546
Type
Preprint
Design
Retrospective propensity-matched cohort, TriNetX electronic health records, 424,269 per arm, initiations Jun 2021–Aug 2026, one-year follow-up
Verdict
Refines prior evidence
Driver
Heart and stroke
Driver
Obesity, diabetes and GLP-1
Abstract — the authors' own words, CC BY

ABSTRACT

Background

Tirzepatide and semaglutide improve functional status and heart failure (HF) events in patients with obesity and HF with preserved ejection fraction. Tirzepatide has been associated with greater control of cardiometabolic risk factors in patients with obesity compared to semaglutide. Whether tirzepatide is associated with lower risk of new-onset HF than semaglutide in patients with obesity is underexplored. Methods

A retrospective cohort study was conducted using data pooled from the TriNetX platform. Patients with obesity who initiated therapy with tirzepatide or semaglutide during the period Jun 4, 2021 to Aug 13, 2026 were identified and 1:1 propensity-score matched to produce two study cohorts. The one-year incidence of new-onset HF was calculated and compared between the two cohorts. Secondary outcomes included new-onset systolic HF, new-onset diastolic heart failure, new-onset atrial fibrillation or flutter, all-cause mortality, and hospital encounters. Cox proportional hazards models were fitted to calculate hazard ratios (HR) along with 95% confidence intervals (CI). Results

Two well-matched cohorts (N=424,269 in each) were formed. The incidence of new-onset HF was lower in the tirzepatide group (1.0% vs. 1.3%; absolute risk difference −0.3%, 95% CI −0.35 to −0.26; HR 0.9, 95% CI 0.86─0.93). The tirzepatide group were also at lower risk of all-cause mortality (HR, 95% CI: 0.8, 0.77─0.91) and new-onset systolic HF (0.8, 0.79─0.92). All other secondary outcomes occurred at similar rates in both study groups. Conclusion

Among patients with obesity, tirzepatide therapy was associated with lower risk of new-onset HF compared to semaglutide although the effect sizes were modest.

Other drivers in Health today